43 results on '"Stevens-Ayers T"'
Search Results
2. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation
- Author
-
Storek, J, Dawson, M A, Lim, L C-L, Burman, B E, Stevens-Ayers, T, Viganego, F, Herremans, M M P T, Flowers, M E D, Witherspoon, R P, Maloney, D G, and Boeckh, M
- Published
- 2004
- Full Text
- View/download PDF
3. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation
- Author
-
Storek, J, primary, Dawson, M A, additional, Lim, L C-L, additional, Burman, B E, additional, Stevens-Ayers, T, additional, Viganego, F, additional, Herremans, M M P T, additional, Flowers, M E D, additional, Witherspoon, R P, additional, Maloney, D G, additional, and Boeckh, M, additional
- Published
- 2003
- Full Text
- View/download PDF
4. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation.
- Author
-
Boeckh M, Stevens-Ayers T, Bowden RA, Boeckh, M, Stevens-Ayers, T, and Bowden, R A
- Abstract
In a prospective study, the cytomegalovirus (CMV) pp65 antigenemia assay was compared with detection of CMV by blood culture in 67 consecutive CMV-seropositive patients undergoing autologous marrow or peripheral blood stem cell transplantation. Antigenemia occurred in 26 patients (38.8%) a median of 33 days (range, 12-74) after transplant. Viremia was detected in 5 patients (7.5%) a median of 30 days (range, 12-74) after transplant and was treated with ganciclovir in 3. Antigenemia occurred sporadically at low levels (< 5 positive cells/slide) in 19 patients (28.4%) and never resulted in CMV disease. Two of 7 patients who presented with or progressed to antigenemia of > 5 positive cells/slide developed fatal CMV pneumonia 8 days later. Neither patient had CMV viremia before onset of pneumonia. Thus, quantitative CMV pp65 antigenemia may be useful in guiding antiviral treatment in seropositive autograft recipients. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
5. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence
- Author
-
Landry, M L, primary, Ferguson, D, additional, Stevens-Ayers, T, additional, de Jonge, M W, additional, and Boeckh, M, additional
- Published
- 1996
- Full Text
- View/download PDF
6. Factors influencing detection of quantitative cytomegalovirus antigenemia
- Author
-
Boeckh, M, primary, Woogerd, P M, additional, Stevens-Ayers, T, additional, Ray, C G, additional, and Bowden, R A, additional
- Published
- 1994
- Full Text
- View/download PDF
7. Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis.
- Author
-
Zamora D, Dasgupta S, Stevens-Ayers T, Edmison B, Winston DJ, Razonable RR, Mehta AK, Lyon GM, Boeckh M, Singh N, Koelle DM, and Limaye AP
- Subjects
- Humans, Male, Middle Aged, Female, Adult, Transplant Recipients, Aged, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Antibodies, Viral immunology, Antibodies, Viral blood, Viremia immunology, Liver Transplantation, Cytomegalovirus Infections immunology, Cytomegalovirus Infections prevention & control, Antiviral Agents therapeutic use, Cytomegalovirus immunology, Killer Cells, Natural immunology
- Abstract
CMV-specific T cells, NK cells, and neutralizing antibodies (nAbs) were assessed in a randomized trial of CMV prevention with preemptive antiviral therapy (PET) versus prophylactic antiviral therapy (PRO) in donor-seropositive/recipient-seronegative (D+R-) liver transplant recipients (LTxR) at 100 days (end of intervention) and at 6 and 12 months after transplant. The PET group had significantly increased numbers of circulating polyfunctional T cells, NK cells, and nAbs compared with the PRO group at day 100, and several CMV immune parameters remained significantly higher by 12 months after transplant. Among PET recipients, preceding CMV viremia (vs. no preceding viremia) was associated with significantly higher levels of most CMV immune parameters at day 100. Higher numbers of CMV-specific polyfunctional T cells and NKG2C+ NK cells at day 100 were associated with a decreased incidence of CMV disease in multivariable Cox regression. The strongest associations with protection against CMV disease were with increased numbers of CMV-specific polyfunctional CD4+ T cells, CD3negCD56dimCD57negNKG2Cpos cells, and CD3negCD56dimCD57posNKG2Cpos NK cells. Our results suggest that PET is superior to PRO for CMV disease prevention by allowing low-level CMV replication and associated antigen exposure that is promptly controlled by antiviral therapy and facilitates enhanced CMV protective immunity in D+R- LTxR.
- Published
- 2024
- Full Text
- View/download PDF
8. The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients.
- Author
-
Boonyaratanakornkit J, Wang Q, Nader A, Kimball L, Stevens-Ayers T, Levkova M, Blazevic R, Nguyen J, Wright J, Castor J, Greninger AL, Ford E, Mielcarek M, Fordred S, Han J, Boeckh M, and Waghmare A
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, SARS-CoV-2 immunology, COVID-19 Drug Treatment, Transplant Recipients, COVID-19, Hematopoietic Stem Cell Transplantation adverse effects, Graft vs Host Disease drug therapy, Diarrhea drug therapy, Antibodies, Monoclonal, Humanized pharmacokinetics, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage
- Abstract
Background: Monoclonal antibodies (mAbs) are utilized broadly to treat cancer and infectious diseases, and mAb exposure (serum concentration over time) is one predictor of overall treatment efficacy. Herein, we present findings from a clinical trial evaluating the pharmacokinetics of the long-acting mAb sotrovimab targeting severe acute respiratory syndrome coronavirus 2 in hematopoietic cell transplant (HCT) recipients., Methods: All participants received an intravenous infusion of sotrovimab within 1 week prior to initiating the pretransplant preparative regimen. The serum concentration of sotrovimab was measured longitudinally for up to 24 weeks posttransplant., Results: Compared to non-HCT participants, we found that mAb clearance was 10% and 26% higher in autologous and allogeneic HCT recipients, respectively. Overall sotrovimab exposure was approximately 15% lower in HCT recipients compared to non-HCT recipients. Exposure was significantly reduced in HCT recipients who developed diarrhea and lower gastrointestinal graft-versus-host disease (GVHD) posttransplant., Conclusions: These data show that sotrovimab exposure may be reduced in HCT recipients, possibly related to increased gastrointestinal clearance in patients with GVHD. This phenomenon has implications for dose selection and duration of efficacy with sotrovimab and potentially other mAbs in this vulnerable patient population. Thus, mAb dose regimens developed in non-HCT populations may have to be optimized when applied to HCT populations., Competing Interests: Potential conflicts of interest. Q. W., A. N., S. F., and J. H. are employees of and hold shares in GSK. A. L. G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic and research support from Gilead, outside of the described work. M. B. reports research support from Merck and consulting for Moderna and AstraZeneca, outside of the described work. A. W. reports research support from Ansun Biopharma, Allovir, and Pfizer and consulting for Vir Biotechnology and GlaxoSmithKline, outside of the described work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
9. Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant.
- Author
-
Heldman MR, Ahmed AA, Liu W, Vo A, Keane-Candib J, Stevens-Ayers T, Boeckh M, Blauwkamp TA, Fisher CE, and Hill JA
- Subjects
- Humans, Retrospective Studies, Fungi, Lung, Aspergillus genetics, Hematopoietic Stem Cell Transplantation adverse effects, Cell-Free Nucleic Acids
- Abstract
Background: Plasma microbial cell-free DNA sequencing (mcfDNA-Seq) is a noninvasive test for microbial diagnosis of invasive mold infection (IMI). The utility of mcfDNA-Seq for predicting IMI onset and the clinical implications of mcfDNA concentrations are unknown., Methods: We retrospectively tested plasma from hematopoietic cell transplant (HCT) recipients with pulmonary IMI and ≥1 mold identified by mcfDNA-Seq in plasma collected within 14 days of clinical diagnosis. Samples collected from up to 4 weeks before and 4 weeks after IMI diagnosis were evaluated using mcfDNA-Seq., Results: Thirty-five HCT recipients with 39 IMIs (16 Aspergillus and 23 non-Aspergillus infections) were included. Pathogenic molds were detected in 38%, 26%, 11%, and 0% of samples collected during the first, second, third, and fourth week before clinical diagnosis, respectively. In non-Aspergillus infections, median mcfDNA concentrations in samples collected within 3 days of clinical diagnosis were higher in infections with versus without extrapulmonary spread (4.3 vs 3.3 log10 molecules per microliter [mpm], P = .02), and all patients (8/8) with mcfDNA concentrations >4.0 log10 mpm died within 42 days after clinical diagnosis., Conclusions: Plasma mcfDNA-Seq can identify pathogenic molds up to 3 weeks before clinical diagnosis of pulmonary IMI. Plasma mcfDNA concentrations may correlate with extrapulmonary spread and mortality in non-Aspergillus IMI., Competing Interests: Potential conflicts of interest . T. A. B. is an employee of Karius, and A. A. A. has stock equity in Karius and was employed by Karius at the time the project was conceived and executed. M. B. received consulting fees from Merck; and research support from Merck and Gilead Sciences. J. A. H received consulting fees from Karius and Pfizer; and research support from Karius, Amplyx, and Merck. C. e. F received research support from Karius. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
10. High-frequency home self-collection of capillary blood correlates IFI27 expression kinetics with SARS-CoV-2 viral clearance.
- Author
-
Lim FY, Kim SY, Kulkarni KN, Blazevic RL, Kimball LE, Lea HG, Haack AJ, Gower MS, Stevens-Ayers T, Starita LM, Boeckh M, Hyrien O, Schiffer JT, Theberge AB, and Waghmare A
- Subjects
- Humans, Kinetics, Antibodies, Viral, Membrane Proteins, SARS-CoV-2, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
11. BK Viremia and Changes in Estimated Glomerular Filtration Rate in Children and Young Adults after Hematopoietic Cell Transplantation.
- Author
-
Wychera C, Imlay HN, Duke ER, Faino A, Li-Huang M, Stevens-Ayers T, Davis C, Lange-Sperandio B, Mallhi KK, Hill JA, Boeckh M, Englund JA, and Hingorani S
- Subjects
- Humans, Child, Young Adult, Adult, Viremia diagnosis, Viremia epidemiology, Glomerular Filtration Rate, Kidney, Kidney Diseases, Hematopoietic Stem Cell Transplantation, BK Virus
- Abstract
Kidney disease in allogeneic hematopoietic cell transplantation (HCT) recipients is associated with increased mortality rates. BK virus (BKV) viremia has been associated with kidney dysfunction in pediatric HCT recipients; however, few studies have investigated longer-term kidney outcomes in association with BKV in this population. Here we assessed the relationship between BK viremia and changes in estimated glomerular filtration rate (eGFR) in children in the first year post-HCT. We selected 136 patients age ≤26 years who underwent HCT in 2007 to 2018 at a single center and had plasma BK viral load data available at 2 time points, weeks 4 to 7 post-HCT and weeks 10 to 13 post-HCT from prospectively collected stored plasma samples. A total of 272 samples were analyzed for BKV using quantitative PCR. We used multivariate linear models to determine the association of BK viremia and change in eGFR by 1 year post-HCT. Forty percent of the patients (54 of 136) had BKV detection in weeks 4 to 7, 13% of whom (7 of 54) had a BK viral load of ≥10,000 copies/mL, and 46% (62 of 136) had BKV detected in weeks 10 to 13, 34% (21 of 62) of whom had a BK viral load of ≥10,000 copies/mL. The mean decline in eGFR was 25.73 mL/min/1.73 m
2 by 1 year post-HCT. In multivariate models, a BK viral load of ≥10,000 copies/mL during weeks 4 to 7 was associated with a mean decline in eGFR of 30.6 mL/min/1.73 m2 (95% confidence interval, -55.94 to -5.17; P = .019) compared with a BK viral load <10,000 copies/mL. In adjusted analyses, a high BK viral load in the blood (≥10,000 copies/mL) was associated with a significant decline in eGFR by 1 year post-HCT., (Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
12. Longitudinal home self-collection of capillary blood using home RNA correlates interferon and innate viral defense pathways with SARS-CoV-2 viral clearance.
- Author
-
Lim FY, Kim SY, Kulkarni KN, Blazevic RL, Kimball LE, Lea HG, Haack AJ, Gower MS, Stevens-Ayers T, Starita LM, Boeckh M, Schiffer JT, Hyrien O, Theberge AB, and Waghmare A
- Abstract
Blood transcriptional profiling is a powerful tool to evaluate immune responses to infection; however, blood collection via traditional phlebotomy remains a barrier to precise characterization of the immune response in dynamic infections (e.g., respiratory viruses). Here we present an at-home self-collection methodology, home RNA, to study the host transcriptional response during acute SARS-CoV-2 infections. This method uniquely enables high frequency measurement of the host immune kinetics in non-hospitalized adults during the acute and most dynamic stage of their infection. COVID-19+ and healthy participants self-collected blood every other day for two weeks with daily nasal swabs and symptom surveys to track viral load kinetics and symptom burden, respectively. While healthy uninfected participants showed remarkably stable immune kinetics with no significant dynamic genes, COVID-19+ participants, on the contrary, depicted a robust response with over 418 dynamic genes associated with interferon and innate viral defense pathways. When stratified by vaccination status, we detected distinct response signatures between unvaccinated and breakthrough (vaccinated) infection subgroups; unvaccinated individuals portrayed a response repertoire characterized by higher innate antiviral responses, interferon signaling, and cytotoxic lymphocyte responses while breakthrough infections portrayed lower levels of interferon signaling and enhanced early cell-mediated response. Leveraging cross-platform longitudinal sampling (nasal swabs and blood), we observed that IFI27, a key viral response gene, tracked closely with SARS-CoV-2 viral clearance in individual participants. Taken together, these results demonstrate that at-home sampling can capture key host antiviral responses and facilitate frequent longitudinal sampling to detect transient host immune kinetics during dynamic immune states.
- Published
- 2023
- Full Text
- View/download PDF
13. Chromosome-Specific Human Herpesvirus 6 Integration and Hematologic Malignancies.
- Author
-
Heldman MR, Wight DJ, Aiewsakun P, Aswad A, Fang M, Roychoudhury P, Stevens-Ayers T, Jerome KR, Zerr DM, Greninger AL, Kaufer BB, Boeckh M, and Hill JA
- Subjects
- Chromosomes, DNA, Viral, Humans, Virus Integration genetics, Hematologic Neoplasms genetics, Herpesvirus 6, Human genetics, Roseolovirus Infections
- Published
- 2022
- Full Text
- View/download PDF
14. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.
- Author
-
Tortorici MA, Walls AC, Joshi A, Park YJ, Eguia RT, Miranda MC, Kepl E, Dosey A, Stevens-Ayers T, Boeckh MJ, Telenti A, Lanzavecchia A, King NP, Corti D, Bloom JD, and Veesler D
- Subjects
- Animals, CD13 Antigens chemistry, CD13 Antigens metabolism, Cats, Cell Line, Dogs, Humans, Receptors, Virus metabolism, Spike Glycoprotein, Coronavirus metabolism, Swine, Coronavirus metabolism, Coronavirus 229E, Human metabolism, Coronavirus Infections
- Abstract
The isolation of CCoV-HuPn-2018 from a child respiratory swab indicates that more coronaviruses are spilling over to humans than previously appreciated. We determined the structures of the CCoV-HuPn-2018 spike glycoprotein trimer in two distinct conformational states and showed that its domain 0 recognizes sialosides. We identified that the CCoV-HuPn-2018 spike binds canine, feline, and porcine aminopeptidase N (APN) orthologs, which serve as entry receptors, and determined the structure of the receptor-binding B domain in complex with canine APN. The introduction of an oligosaccharide at position N739 of human APN renders cells susceptible to CCoV-HuPn-2018 spike-mediated entry, suggesting that single-nucleotide polymorphisms might account for viral detection in some individuals. Human polyclonal plasma antibodies elicited by HCoV-229E infection and a porcine coronavirus monoclonal antibody inhibit CCoV-HuPn-2018 spike-mediated entry, underscoring the cross-neutralizing activity among ɑ-coronaviruses. These data pave the way for vaccine and therapeutic development targeting this zoonotic pathogen representing the eighth human-infecting coronavirus., Competing Interests: Declaration of interests A.T., A.L., and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. D.C. is currently listed as an inventor on multiple patent applications, which disclose the subject matter described in this manuscript. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
15. Convergent clonal selection of donor- and recipient-derived CMV-specific T cells in hematopoietic stem cell transplant patients.
- Author
-
Erickson JR, Stevens-Ayers T, Mair F, Edmison B, Boeckh M, Bradley P, and Prlic M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, CD8-Positive T-Lymphocytes immunology, Cytomegalovirus physiology, Cytomegalovirus Infections immunology, Hematopoietic Stem Cell Transplantation, Memory T Cells immunology, Tissue Donors, Virus Activation immunology
- Abstract
Competition between antigen-specific T cells for peptide:MHC complexes shapes the ensuing T cell response. Mouse model studies provided compelling evidence that competition is a highly effective mechanism controlling the activation of naïve T cells. However, assessing the effect of T cell competition in the context of a human infection requires defined pathogen kinetics and trackable naïve and memory T cell populations of defined specificity. A unique cohort of nonmyeloablative hematopoietic stem cell transplant patients allowed us to assess T cell competition in response to cytomegalovirus (CMV) reactivation, which was documented with detailed virology data. In our cohort, hematopoietic stem cell transplant donors and recipients were CMV seronegative and positive, respectively, thus providing genetically distinct memory and naïve T cell populations. We used single-cell transcriptomics to track donor versus recipient-derived T cell clones over the course of 90 d. We found that donor-derived T cell clones proliferated and expanded substantially following CMV reactivation. However, for immunodominant CMV epitopes, recipient-derived memory T cells remained the overall dominant population. This dominance was maintained despite more robust clonal expansion of donor-derived T cells in response to CMV reactivation. Interestingly, the donor-derived T cells that were recruited into these immunodominant memory populations shared strikingly similar TCR properties with the recipient-derived memory T cells. This selective recruitment of identical and nearly identical clones from the naïve into the immunodominant memory T cell pool suggests that competition is in place but does not interfere with rejuvenating a memory T cell population. Instead, it results in selection of convergent clones to the memory T cell pool., Competing Interests: The authors declare no competing interest., (Copyright © 2022 the Author(s). Published by PNAS.)
- Published
- 2022
- Full Text
- View/download PDF
16. Liquid Biopsy for Invasive Mold Infections in Hematopoietic Cell Transplant Recipients With Pneumonia Through Next-Generation Sequencing of Microbial Cell-Free DNA in Plasma.
- Author
-
Hill JA, Dalai SC, Hong DK, Ahmed AA, Ho C, Hollemon D, Blair L, Maalouf J, Keane-Candib J, Stevens-Ayers T, Boeckh M, Blauwkamp TA, and Fisher CE
- Subjects
- Fungi, High-Throughput Nucleotide Sequencing, Humans, Liquid Biopsy, Retrospective Studies, Transplant Recipients, Cell-Free Nucleic Acids, Hematopoietic Stem Cell Transplantation adverse effects, Pneumonia
- Abstract
Background: Noninvasive diagnostic options are limited for invasive mold infections (IMIs). We evaluated the performance of a plasma microbial cell-free DNA sequencing (mcfDNA-Seq) test for diagnosing pulmonary IMI after hematopoietic cell transplant (HCT)., Methods: We retrospectively assessed the diagnostic performance of plasma mcfDNA-Seq next-generation sequencing in 114 HCT recipients with pneumonia after HCT who had stored plasma obtained within 14 days of diagnosis of proven/probable Aspergillus IMI (n = 51), proven/probable non-Aspergillus IMI (n = 24), possible IMI (n = 20), and non-IMI controls (n = 19). Sequences were aligned to a database including >400 fungi. Organisms above a fixed significance threshold were reported., Results: Among 75 patients with proven/probable pulmonary IMI, mcfDNA-Seq detected ≥1 pathogenic mold in 38 patients (sensitivity, 51% [95% confidence interval {CI}, 39%-62%]). When restricted to samples obtained within 3 days of diagnosis, sensitivity increased to 61%. McfDNA-Seq had higher sensitivity for proven/probable non-Aspergillus IMI (sensitivity, 79% [95% CI, 56%-93%]) compared with Aspergillus IMI (sensitivity, 31% [95% CI, 19%-46%]). McfDNA-Seq also identified non-Aspergillus molds in an additional 7 patients in the Aspergillus subgroup and Aspergillus in 1 patient with possible IMI. Among 19 non-IMI pneumonia controls, mcfDNA-Seq was negative in all samples, suggesting a high specificity (95% CI, 82%-100%) and up to 100% positive predictive value (PPV) with estimated negative predictive values (NPVs) of 81%-99%. The mcfDNA-Seq assay was complementary to serum galactomannan index testing; in combination, they were positive in 84% of individuals with proven/probable pulmonary IMI., Conclusions: Noninvasive mcfDNA-Seq had moderate sensitivity and high specificity, NPV, and PPV for pulmonary IMI after HCT, particularly for non-Aspergillus species., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
17. Association of Inherited Chromosomally Integrated Human Herpesvirus 6 with Neurologic Symptoms and Management after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Heldman MR, Job C, Maalouf J, Morris J, Xie H, Davis C, Stevens-Ayers T, Huang ML, Jerome KR, Fann JR, Zerr DM, Boeckh M, and Hill JA
- Subjects
- Cohort Studies, Humans, Retrospective Studies, Tissue Donors, Hematopoietic Stem Cell Transplantation adverse effects, Herpesvirus 6, Human genetics
- Abstract
Reactivation of human herpesvirus 6 (HHV-6) after allogeneic hematopoietic cell transplantation (HCT) is associated with neurologic complications, but the impact of donor and/or recipient inherited chromosomally integrated HHV-6 (iciHHV-6) on post-HCT central nervous system (CNS) symptoms and diagnostic and therapeutic interventions is not well understood. The aims of the present study were (1) to compare the cumulative incidence of CNS symptoms in the first 100 days following allogeneic HCT among patients with donor and/or recipient iciHHV-6 (iciHHV-6
pos )with that of patients with neither donor nor recipient iciHHV-6 (iciHHV-6neg ) and (2) to assess the role of HHV-6 detection in driving potentially unnecessary interventions in iciHHV-6pos patients. We performed a retrospective matched cohort study of 87 iciHHV-6pos and 174 iciHHV-6neg allogeneic HCT recipients. HHV-6 testing was performed at the discretion of healthcare providers, who were unaware of iciHHV-6 status. The cumulative incidence of CNS symptoms was similar in iciHHV-6pos (n = 37; 43%) and iciHHV-6neg HCT recipients (n = 81; 47%; P = .63). HHV-6 plasma testing was performed in similar proportions of iciHHV-6pos (n = 6; 7%) and iciHHV-6neg (9%) patients and was detected in all tested iciHHV-6pos HCTs and 2 (13%) iciHHV-6neg HCTs. This resulted in more frequent HHV-6-targeted antiviral therapy after iciHHV-6pos HCT (odds ratio, 12.8; 95% confidence interval, 1.5 to 108.2) with associated side effects. HHV-6 plasma detection in 2 iciHHV-6pos patients without active CNS symptoms prompted unnecessary lumbar punctures. The cumulative incidence of CNS symptoms was similar after allogeneic HCT involving recipients or donors with and without iciHHV-6. Misattribution of HHV-6 detection as infection after iciHHV-6pos HCT may lead to unnecessary interventions. Testing for iciHHV-6 may improve patient management., (Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
18. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.
- Author
-
Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, Stevens-Ayers T, Wagner R, Mielcarek M, Leisenring WM, Jerome KR, Schiffer JT, Finak G, De Rosa SC, and Boeckh M
- Subjects
- Adult, Aged, Cytomegalovirus drug effects, Cytomegalovirus Infections immunology, Cytomegalovirus Infections virology, Disease-Free Survival, Female, Humans, Linear Models, Lymphocyte Count, Male, Middle Aged, Multivariate Analysis, Phenotype, T-Lymphocytes drug effects, Virus Activation drug effects, Young Adult, Acetates pharmacology, Cytomegalovirus immunology, Hematopoietic Stem Cell Transplantation, Quinazolines pharmacology, T-Lymphocytes immunology
- Abstract
Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir prophylaxis-associated reduction in viral exposure influences CMV-specific immune reconstitution is unknown. In a prospective cohort of allogeneic HCT recipients who received letermovir, we compared polyfunctional CMV-specific T-cell responses to those of controls who received PCR-guided preemptive therapy before the introduction of letermovir. Thirteen-color flow cytometry was used to assess T-cell responses at 3 months after HCT following stimulation with CMV immediate early-1 (IE-1) antigen and phosphoprotein 65 (pp65) antigens. Polyfunctionality was characterized by combinatorial polyfunctionality analysis of antigen-specific T-cell subsets. Use of letermovir and reduction of viral exposure were assessed for their association with CMV-specific T-cell immunity. Polyfunctional T-cell responses to IE-1 and pp65 were decreased in letermovir recipients and remained diminished after adjustment for donor CMV serostatus, absolute lymphocyte count, and steroid use. Among letermovir recipients, greater peak CMV DNAemia and increased viral shedding were associated with stronger CD8+ responses to pp65, whereas the CMV shedding rate was associated with greater CD4+ responses to IE-1. In summary, our study provided initial evidence that letermovir may delay CMV-specific cellular reconstitution, possibly related to decreased CMV antigen exposure. Evaluating T-cell polyfunctionality may identify patients at risk for late CMV infection after HCT., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
19. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
- Author
-
Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, and Hill JA
- Subjects
- Adolescent, Adult, Aged, Antigens, CD19, B-Cell Maturation Antigen, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infant, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Male, Middle Aged, Multiple Myeloma therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Prospective Studies, Vaccine-Preventable Diseases immunology, Young Adult, Agammaglobulinemia immunology, Antibodies, Bacterial immunology, Antibodies, Viral immunology, Immunity, Humoral immunology, Immunoglobulin G immunology, Immunotherapy, Adoptive, Leukemia, B-Cell therapy, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen, Vaccine-Preventable Diseases prevention & control
- Abstract
BACKGROUNDLittle is known about pathogen-specific humoral immunity after chimeric antigen receptor-modified T (CAR-T) cell therapy for B cell malignancies.METHODSWe conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen-targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected ("epitope hits") using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections.RESULTSWe enrolled 65 children and adults a median of 20 months after CD19- (n = 54) or BCMA- (n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%-73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18-1.25) and had fewer pathogen-specific epitope hits (mean difference, -90 epitope hits; 95% CI, -157 to -22).CONCLUSIONSeroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies.FUNDINGSwiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- Published
- 2021
- Full Text
- View/download PDF
20. A human coronavirus evolves antigenically to escape antibody immunity.
- Author
-
Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA, Boeckh MJ, and Bloom JD
- Subjects
- Humans, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Coronavirus 229E, Human genetics, Coronavirus 229E, Human immunology, Immune Evasion
- Abstract
There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these "future" viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers >1:100 do not detectably neutralize strains isolated 8-17 years later. The decreased neutralization of "future" viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: MJB has consulted for Moderna and Vir Biotechnologies, and received research funding from Regeneron and Vir Biotechnologies. JAE has consulted for Meissa Vaccines and Sanofi Pasteur, and received research funding from Merck, GlaxoSmithKline, Pfizer, and AstraZeneca. The other authors declare no competing interests.
- Published
- 2021
- Full Text
- View/download PDF
21. Donor-Derived CD4+ T Cells and Human Herpesvirus 6B Detection After Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Hanson DJ, Xie H, Zerr DM, Leisenring WM, Jerome KR, Huang ML, Stevens-Ayers T, Boeckh M, Koelle DM, and Hill JA
- Subjects
- Adult, Female, Herpesvirus 6, Human genetics, Herpesvirus 6, Human immunology, Humans, Lymphocyte Count, Male, Middle Aged, Tissue Donors, Viral Load, CD4-Positive T-Lymphocytes immunology, Hematopoietic Stem Cell Transplantation, Herpesvirus 6, Human isolation & purification
- Abstract
We sought to determine whether donor-derived human herpesvirus (HHV) 6B-specific CD4+ T-cell abundance is correlated with HHV-6B detection after allogeneic hematopoietic cell transplantation. We identified 33 patients who received HLA-matched, non-T-cell-depleted, myeloablative allogeneic hematopoietic cell transplantation and underwent weekly plasma polymerase chain reaction testing for HHV-6B for 100 days thereafter. We tested donor peripheral blood mononuclear cells for HHV-6B-specific CD4+ T cells. Patients with HHV-6B detection above the median peak viral load (200 copies/mL) received approximately 10-fold fewer donor-derived total or HHV-6B-specific CD4+ T cells than those with peak HHV-6B detection at ≤200 copies/mL or with no HHV-6B detection. These data suggest the importance of donor-derived immunity for controlling HHV-6B reactivation., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
22. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation.
- Author
-
Duke ER, Williamson BD, Borate B, Golob JL, Wychera C, Stevens-Ayers T, Huang ML, Cossrow N, Wan H, Mast TC, Marks MA, Flowers ME, Jerome KR, Corey L, Gilbert PB, Schiffer JT, and Boeckh M
- Subjects
- Allografts, Female, Humans, Male, Retrospective Studies, Cytomegalovirus genetics, Cytomegalovirus metabolism, Cytomegalovirus Infections blood, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections etiology, Cytomegalovirus Infections mortality, Ganciclovir administration & dosage, Hematopoietic Stem Cell Transplantation, Viral Load
- Abstract
BACKGROUNDViral load (VL) surrogate endpoints transformed development of HIV and hepatitis C therapeutics. Surrogate endpoints for CMV-related morbidity and mortality could advance development of antiviral treatments. Although observational data support using CMV VL as a trial endpoint, randomized controlled trials (RCTs) demonstrating direct associations between virological markers and clinical endpoints are lacking.METHODSWe performed CMV DNA PCR on frozen serum samples from the only placebo-controlled RCT of ganciclovir for early treatment of CMV after hematopoietic cell transplantation (HCT). We used established criteria to assess VL kinetics as surrogates for CMV disease or death by weeks 8, 24, and 48 after randomization and quantified antiviral effects captured by each marker. We used ensemble-based machine learning to assess the predictive ability of VL kinetics and performed this analysis on a ganciclovir prophylaxis RCT for validation.RESULTSVL suppression with ganciclovir reduced cumulative incidence of CMV disease and death for 20 years after HCT. Mean VL, peak VL, and change in VL during the first 5 weeks of treatment fulfilled the Prentice definition for surrogacy, capturing more than 95% of ganciclovir's effect, and yielded highly sensitive and specific predictions by week 48. In the prophylaxis trial, the viral shedding rate satisfied the Prentice definition for CMV disease by week 24.CONCLUSIONSOur results support using CMV VL kinetics as surrogates for CMV disease, provide a framework for developing CMV preventative and therapeutic agents, and support reductions in VL as the mechanism through which antivirals reduce CMV disease.FUNDINGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Published
- 2021
- Full Text
- View/download PDF
23. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
- Author
-
Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, and Limaye AP
- Subjects
- Adult, Aged, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections transmission, Cytomegalovirus Infections virology, Female, Humans, Incidence, Male, Middle Aged, Polymerase Chain Reaction, Tissue Donors, Viral Load, Viremia diagnosis, Antibiotic Prophylaxis, Antiviral Agents therapeutic use, Cytomegalovirus isolation & purification, Cytomegalovirus Infections prevention & control, Liver Transplantation, Valganciclovir therapeutic use, Viremia drug therapy
- Abstract
Importance: Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, high rates of delayed-onset postprophylaxis CMV disease occur. An alternate approach, preemptive therapy (initiation of antiviral therapy for early asymptomatic CMV viremia detected by surveillance testing), has not previously been directly compared with antiviral prophylaxis in these patients., Objective: To compare preemptive therapy with antiviral prophylaxis in CMV-seronegative liver transplant recipients with seropositive donors for the prevention of CMV disease., Design, Setting, and Participants: Randomized clinical trial of preemptive therapy vs antiviral prophylaxis in 205 CMV-seronegative liver transplant recipients with seropositive donors aged older than 18 years. The trial was conducted at 6 academic transplant centers in the United States between October 2012 and June 2017, with last follow-up in June 2018., Interventions: Patients were randomized 1:1 to receive either preemptive therapy (valganciclovir, 900 mg, twice daily until 2 consecutive negative tests a week apart) for viremia detected by weekly plasma CMV polymerase chain reaction for 100 days (n = 100) or valganciclovir, 900 mg, daily for 100 days as antiviral prophylaxis (n = 105)., Main Outcomes and Measures: The primary outcome was incidence of CMV disease by 12 months, defined as CMV syndrome (CMV viremia and clinical or laboratory findings) or end-organ disease. Secondary outcomes included acute allograft rejection, opportunistic infections, graft and patient survival, and neutropenia., Results: Among 205 patients who were randomized (mean age, 55 years; 62 women [30%]), all 205 (100%) completed the trial. The incidence of CMV disease was significantly lower with preemptive therapy than antiviral prophylaxis (9% [9/100] vs 19% [20/105]; difference, 10% [95% CI, 0.5% to 19.6%]; P = .04]). The incidence of allograft rejection (28% vs 25%; difference, 3% [95% CI, -9% to 15%]), opportunistic infections (25% vs 27%; difference, 2% [95% CI, -14% to 10%]), graft loss (2% vs 2%; difference, <1% [95% CI, -4% to 4%]), and neutropenia (13% vs 10%; difference, 3% [95% CI, -5% to 12%]) did not differ significantly for the preemptive therapy vs antiviral prophylaxis group, respectively. All-cause mortality at last follow-up was 15% in the preemptive therapy vs 19% in the antiviral prophylaxis group (difference, 4% [95% CI, -14% to 6%]; P = .46)., Conclusions and Relevance: Among CMV-seronegative liver transplant recipients with seropositive donors, the use of preemptive therapy, compared with antiviral prophylaxis, resulted in a lower incidence of CMV disease over 12 months. Further research is needed to replicate these findings and assess long-term outcomes., Trial Registration: ClinicalTrials.gov Identifier: NCT01552369.
- Published
- 2020
- Full Text
- View/download PDF
24. Cytomegalovirus Humoral Response Against Epithelial Cell Entry-Mediated Infection in the Primary Infection Setting After Hematopoietic Cell Transplantation.
- Author
-
Zamora D, Krantz EM, Green ML, Joncas-Schronce L, Blazevic R, Edmison BC, Huang ML, Stevens-Ayers T, Jerome KR, Geballe AP, and Boeckh M
- Subjects
- Adolescent, Adult, Antibodies, Viral immunology, Child, Child, Preschool, Cytomegalovirus, Cytomegalovirus Infections drug therapy, Epithelial Cells drug effects, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Male, Middle Aged, Tissue Donors, Transplant Recipients, Viral Load drug effects, Young Adult, Antibodies, Neutralizing immunology, Antiviral Agents administration & dosage, Cytomegalovirus Infections immunology, Cytomegalovirus Infections prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Immunity, Humoral
- Abstract
Background: The influence of humoral immunity on the prevention of primary cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) is poorly understood., Methods: To determine whether neutralizing antibodies (nAbs) against CMV pentameric complex (PC)-mediated epithelial cell entry decrease CMV infection after HCT, samples were analyzed from a randomized controlled trial of CMV intravenous immunoglobulin (IVIG) prophylaxis. Weekly serum from 61 CMV donor-positive/recipient-negative (D+/R-) HCT patients (33 control, 28 CMV IVIG) was tested using a PC-entry nAb assay and quantitative CMV polymerase chain reaction (PCR)., Results: There was a trend toward higher weekly PC-entry nAb titers (P = .07) and decreased CMV infection by PCR at viral load cutoffs of ≥1000 and ≥10 000 IU/mL in the CMV IVIG arm. High nAb titers were not significantly protective against CMV infection later after HCT in both study arms. Among CMV-infected patients, each log2 increase in nAb titer was associated with an average 0.2 log10 decrease in concurrent CMV viral load after infection (P = .001; adjusted for study arm)., Conclusions: This study provides initial support that CMV IVIG prophylaxis moderately enhances PC-entry nAB activity in D+/R- HCT recipients., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
25. Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6.
- Author
-
Weschke DP, Leisenring WM, Lawler RL, Stevens-Ayers T, Huang ML, Jerome KR, Zerr DM, Hansen JA, Boeckh M, and Hill JA
- Subjects
- Acute Disease, Cytokines, Humans, Tissue Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation adverse effects, Herpesvirus 6, Human genetics
- Abstract
Acute graft-versus-host-disease (aGVHD) is a major complication following hematopoietic cell transplantations (HCTs). We have shown that HCT recipients in whom either the donor or patient had inherited chromosomally integrated human herpesvirus 6 (iciHHV-6) have a higher incidence of developing more severe aGVHD. Previous studies established that increased proinflammatory cytokines are associated with increased risk for aGVHD and nonrelapse mortality post-HCT. We hypothesized that HCT recipients with donor or recipient iciHHV-6 (iciHHV-6
pos HCT cases) will have higher cytokine levels compared with HCT recipients without iciHHV-6 (iciHHV-6neg HCT controls). We identified 64 iciHHV-6pos HCT cases with plasma from days 7, 14, and/or 21 post-HCT and before aGVHD onset in patients who developed aGVHD. We identified 64 iciHHV-6neg HCT controls matched for aGVHD risk factors. We also identified 28 donors with iciHHV-6 and 56 matched donors without iciHHV-6. We measured plasma cytokine concentrations for IL-6, suppression of tumorigenicity 2, T cell immunoglobulin and mucin-domain containing 3, TNFα, soluble TNF receptor 1 (TNFRp55), and C-reactive protein (CRP). We used Mann-Whitney tests and repeated-measures models to compare cytokine levels. iciHHV-6pos HCT cases had higher CRP levels on day 7 and day 21 and higher TNFRp55 levels on day 14 and day 21 compared with iciHHV-6neg HCT controls. These findings were recapitulated in a repeated-measures model. The differences were most evident among patients who subsequently developed aGVHD grades 2 to 4. Additionally, iciHHV-6pos HCT cases had earlier-onset aGVHD (median, 20 versus 27 days post-HCT; P = .02). There were no differences in cytokine levels among healthy donors with or without iciHHV-6. This study demonstrates that HCT recipients with iciHHV-6 have higher proinflammatory cytokines that may be associated with increased risk for aGVHD., (Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
26. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
- Author
-
Hill JA, Krantz EM, Hay KA, Dasgupta S, Stevens-Ayers T, Bender Ignacio RA, Bar M, Maalouf J, Cherian S, Chen X, Pepper G, Riddell SR, Maloney DG, Boeckh MJ, and Turtle CJ
- Subjects
- Adult, Aged, Antibodies, Viral blood, Female, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Leukemia, B-Cell immunology, Leukemia, B-Cell therapy, Lymphocyte Depletion, Lymphoma, B-Cell immunology, Lymphoma, B-Cell therapy, Male, Middle Aged, Receptors, Antigen, T-Cell genetics, Time Factors, Young Adult, Antibodies, Viral immunology, Antigens, CD19 immunology, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
The long-term effects of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy (CD19-CARTx) for B-cell malignancies on humoral immunity are unclear. We examined antiviral humoral immunity in 39 adults with B-cell malignancies who achieved durable complete remission without additional therapy for >6 months after CD19-CARTx. Despite CD19+ B-cell aplasia in all patients, the incidence of viral infections occurring >90 days post-CD19-CARTx was low (0.91 infections per person-year). Because long-lived plasma cells are CD19- and should not be direct targets of CD19-targeted chimeric antigen receptor T cells, we tested the hypothesis that humoral immunity was preserved after CD19-CARTx based on linear mixed-effects models of changes in serum total immunoglobulin G (IgG) concentration, measles IgG concentration, and the number of viruses or viral epitopes to which serum IgG was directed (the "antivirome") using the novel VirScan assay. Samples were tested pre-CD19-CARTx and ∼1, 6, and 12 months post-CD19-CARTx. Although total IgG concentration was lower post-CD19-CARTx (mean change, -17.5%), measles IgG concentration was similar (mean change, 1.2%). Only 1 participant lost measles seroprotection post-CD19-CARTx but had undergone allogeneic hematopoietic cell transplantation before CD19-CARTx. The antivirome was also preserved, with mean absolute losses of 0.3 viruses and 6 viral epitopes detected between pre- and post-CD19-CARTx samples. Most participants gained IgG to ≥2 epitopes for ≥2 viruses, suggesting that humoral immunity to some viruses may be maintained or recover after successful CD19-CARTx. These findings may differ in children. Studies of immunoglobulin replacement and vaccination after CARTx are warranted., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
27. Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation.
- Author
-
Hill JA, Vande Vusse LK, Xie H, Chung EL, Yeung CCS, Seo S, Stevens-Ayers T, Fisher CE, Huang ML, Stewart FM, Jerome KR, Zerr DM, Corey L, Leisenring WM, and Boeckh M
- Subjects
- Adult, Antiviral Agents therapeutic use, Bronchoalveolar Lavage Fluid virology, Cohort Studies, DNA, Viral analysis, Female, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cell Transplantation mortality, Herpesvirus 6, Human genetics, Humans, Male, Middle Aged, RNA, Viral analysis, Respiratory Tract Infections drug therapy, Respiratory Tract Infections mortality, Retrospective Studies, Roseolovirus Infections drug therapy, Roseolovirus Infections mortality, Viral Load, Young Adult, Hematopoietic Stem Cell Transplantation adverse effects, Herpesvirus 6, Human isolation & purification, Respiratory Tract Infections virology, Roseolovirus Infections virology
- Abstract
Purpose: Human herpesvirus 6B (HHV-6B) DNA is frequently detected in bronchoalveolar lavage fluid (BALF) from immunocompromised subjects with lower respiratory tract disease (LRTD). Whether HHV-6B is a pulmonary pathogen is unclear., Methods: We tested BALF for HHV-6B DNA using polymerase chain reaction in allogeneic hematopoietic cell transplantation (HCT) recipients who underwent a BAL for evaluation of LRTD from 1992 to 2015. We used multivariable proportional hazards models to evaluate the association of HHV-6B
+ BALF with overall mortality, death from respiratory failure, and the effect of anti-HHV-6B antivirals on these outcomes. We used branched-chain RNA in situ hybridization to detect HHV-6 messenger RNA ( U41 and U57 transcripts) in lung tissue., Results: We detected HHV-6B+ BALF from 147 of 553 (27%) individuals. Subjects with HHV-6B+ BALF, with or without copathogens, had significantly increased risk of overall mortality (adjusted hazard ratio [aHR], 2.18; 95% CI, 1.41-3.39) and death from respiratory failure (aHR, 2.50; 95% CI, 1.56-4.01) compared with subjects with HHV-6B- BALF. Subjects with HHV-6B+ BALF who received antivirals within 3 days pre-BAL had an approximately 1 log10 lower median HHV-6B BALF viral load, as well as a lower risk of overall mortality (aHR, 0.42; 95% CI, 0.16-1.10), compared with subjects with HHV-6B+ BALF not receiving antivirals. We detected intraparenchymal HHV-6 gene expression by RNA in situ hybridization in lung tissue in all three tested subjects with HHV-6B+ BALF and sufficient tissue RNA preservation., Conclusion: These data provide evidence that HHV-6B detection in BALF is associated with higher mortality in allogeneic hematopoietic cell transplantation recipients with LRTD. Definitive evidence of causation will require a randomized prevention or treatment trial.- Published
- 2019
- Full Text
- View/download PDF
28. Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin.
- Author
-
Lee JM, Eguia R, Zost SJ, Choudhary S, Wilson PC, Bedford T, Stevens-Ayers T, Boeckh M, Hurt AC, Lakdawala SS, Hensley SE, and Bloom JD
- Subjects
- Animals, Ferrets, Hemagglutinin Glycoproteins, Influenza Virus genetics, Humans, Influenza, Human immunology, Orthomyxoviridae genetics, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections virology, Serum immunology, Antibodies, Viral blood, Genetic Variation, Hemagglutinin Glycoproteins, Influenza Virus immunology, Immune Evasion, Influenza, Human virology, Mutation, Orthomyxoviridae immunology
- Abstract
A longstanding question is how influenza virus evolves to escape human immunity, which is polyclonal and can target many distinct epitopes. Here, we map how all amino-acid mutations to influenza's major surface protein affect viral neutralization by polyclonal human sera. The serum of some individuals is so focused that it selects single mutations that reduce viral neutralization by over an order of magnitude. However, different viral mutations escape the sera of different individuals. This individual-to-individual variation in viral escape mutations is not present among ferrets that have been infected just once with a defined viral strain. Our results show how different single mutations help influenza virus escape the immunity of different members of the human population, a phenomenon that could shape viral evolution and disease susceptibility., Competing Interests: JL, RE, SZ, SC, PW, TB, TS, MB, AH, SL, SH, JB No competing interests declared, (© 2019, Lee et al.)
- Published
- 2019
- Full Text
- View/download PDF
29. Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation.
- Author
-
Bender Ignacio RA, Dasgupta S, Stevens-Ayers T, Kula T, Hill JA, Lee SJ, Mielcarek M, Duerr A, Elledge SJ, and Boeckh M
- Subjects
- Adult, Antibodies, Viral blood, Antibody Formation genetics, Cytomegalovirus immunology, Female, Follow-Up Studies, Graft vs Host Disease etiology, HLA Antigens genetics, HLA Antigens immunology, Humans, Male, Middle Aged, Postoperative Period, Tissue Donors, Transplant Recipients, Transplantation, Homologous, Antibodies, Viral immunology, Antibody Formation immunology, Epitopes immunology, Hematopoietic Stem Cell Transplantation adverse effects, Immunity, Humoral
- Abstract
Further insight into humoral viral immunity after hematopoietic cell transplantation (HCT) could have potential impact on donor selection or monitoring of patients. Currently, estimation of humoral immune recovery is inferred from lymphocyte counts or immunoglobulin levels and does not address vulnerability to specific viral infections. We interrogated the viral antibody repertoire before and after HCT using a novel serosurvey (VirScan) that detects immunoglobulin G responses to 206 viruses. We performed VirScan on cryopreserved serum from pre-HCT and 30, 100, and 365 days after myeloablative HCT from 37 donor-recipient pairs. We applied ecologic metrics (α- and β-diversity) and evaluated predictors of metrics and changes over time. Donor age and donor/recipient cytomegalovirus (CMV) serostatus and receipt systemic glucocorticoids were most strongly associated with VirScan metrics at day 100. Other clinical characteristics, including pre-HCT treatment and conditioning, did not affect antiviral repertoire metrics. The recipient repertoire was most similar (pairwise β-diversity) to that of donor at day 100, but more similar to pre-HCT self by day 365. Gain or loss of epitopes to common viruses over the year post-HCT differed by donor and recipient pre-HCT serostatus, with highest gains in naive donors to seropositive recipients for several human herpesviruses and adenoviruses. We used VirScan to highlight contributions of donor and recipient to antiviral humoral immunity and evaluate longitudinal changes. This work builds a foundation to test whether such systematic profiling could serve as a biomarker of immune reconstitution, predict clinical events after HCT, or help refine selection of optimal donors., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
30. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
- Author
-
Limaye AP, Green ML, Edmison BC, Stevens-Ayers T, Chatterton-Kirchmeier S, Geballe AP, Singh N, and Boeckh M
- Subjects
- CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes immunology, Cell Line, Cytokines metabolism, Cytomegalovirus drug effects, Cytomegalovirus Infections prevention & control, Drug Administration Schedule, Epithelial Cells, Female, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Risk Factors, Tissue Donors, Transplantation Immunology, Antiviral Agents therapeutic use, Cytomegalovirus immunology, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections immunology, Immunity, Liver Transplantation, Transplant Recipients
- Abstract
The differential impact of preemptive therapy (PET) and antiviral prophylaxis (AP) on development of cytomegalovirus (CMV)-specific neutralizing antibody (nAb) and T-cell responses have not previously been directly compared in high-risk donor-seropositive/recipient-seronegative (D+R-) organ transplant recipients. We prospectively assessed T-cell and nAb responses 3 months after transplantation in cohorts of high-risk D+R- liver transplant recipients who received either PET (n = 15) or AP (n = 25) and a control group of CMV-seropositive transplant recipients (R+) (AP; n = 24). CMV phosphoprotein 65 (pp65)- and immediate early protein 1-specific multifunctional T-cell responses were determined by means of intracellular cytokine staining and nAbs against BADrUL131-Y4 CMV in adult retinal pigment epithelial cell line-19 human epithelial cells; nAbs were detected in 8 of 12 (67%) in the PET group, none of 17 in the AP group, and 20 of 22 (91%) in the R+ group. Multifunctional CD8 and CD4 T-cell responses to pp65 were generally similar between PET and R+ groups, and lower for the AP group; multifunctional CD4 responses were similar across all groups. Among D+R- liver transplant recipients, PET was associated with the development of greater nAb and multifunctional CD8 T-cell responses compared with AP, providing a potential mechanism to explain the relative protection against late-onset disease with PET. Future studies are needed to define specific immune parameters predictive of late-onset CMV disease with AP., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
31. Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Jerome KR, Zerr DM, Nichols G, Boeckh M, and Schiffer JT
- Subjects
- Adult, Area Under Curve, Cytomegalovirus Infections blood, Cytomegalovirus Infections diagnosis, Epstein-Barr Virus Infections blood, Epstein-Barr Virus Infections diagnosis, Female, Humans, Kinetics, Male, Real-Time Polymerase Chain Reaction, Retrospective Studies, Risk Factors, Roseolovirus Infections blood, Roseolovirus Infections diagnosis, Young Adult, DNA blood, DNA, Viral blood, Hematopoietic Stem Cell Transplantation adverse effects, Viral Load, Viremia mortality
- Abstract
Background: Improved understanding of double-stranded DNA (dsDNA) virus kinetics after hematopoietic cell transplantation (HCT) would facilitate development of therapeutic strategies., Methods: We tested weekly plasma samples from 404 patients through day 100 after allogeneic HCT for cytomegalovirus (CMV), human herpesvirus (HHV) 6A and 6B, BK polyomavirus (BKV), adenovirus (AdV), and Epstein-Barr virus (EBV) using quantitative polymerase chain reaction. Episodes lasting ≤1 week were defined as blips and >1 week as persistent. We described virus-specific kinetics, analyzed the association of virus area under the curve (AUC) with overall mortality, and identified risk factors for persistent episodes., Results: We identified 428 episodes of CMV, 292 of BKV, 224 of HHV-6B, 46 of AdV, and 53 of EBV. CMV and BKV had the highest proportions of persistent episodes (68% and 80%, respectively). Detection and kinetics varied by virus. HHV-6B episodes reached maximum levels fastest and had the shortest intervals between detection and end-organ disease. End-organ disease occurred within 14 days of viremia in 68% of cases, generally during persistent episodes. For all viruses, higher viral load AUC increased risk for overall mortality through day 365, persistent episodes had higher viral load than blips, and higher first positive viral load significantly increased risk for persistent episodes. First viral load >2 log10 copies/mL (range, 2.04-3.06 per virus) had high specificity for persistent episodes., Conclusions: Persistent high viral load dsDNA viremia episodes after allogeneic HCT predict mortality. Virus-specific kinetics can guide timing and thresholds for early intervention in studies of novel agents., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
32. Parallel evolution of influenza across multiple spatiotemporal scales.
- Author
-
Xue KS, Stevens-Ayers T, Campbell AP, Englund JA, Pergam SA, Boeckh M, and Bloom JD
- Subjects
- Adult, Aged, Female, High-Throughput Nucleotide Sequencing, Humans, Immunocompromised Host, Longitudinal Studies, Male, Middle Aged, Mutation, RNA, Viral genetics, Sequence Analysis, DNA, Spatio-Temporal Analysis, Evolution, Molecular, Genetic Variation, Influenza A Virus, H3N2 Subtype classification, Influenza A Virus, H3N2 Subtype genetics, Influenza, Human virology
- Abstract
Viral variants that arise in the global influenza population begin as de novo mutations in single infected hosts, but the evolutionary dynamics that transform within-host variation to global genetic diversity are poorly understood. Here, we demonstrate that influenza evolution within infected humans recapitulates many evolutionary dynamics observed at the global scale. We deep-sequence longitudinal samples from four immunocompromised patients with long-term H3N2 influenza infections. We find parallel evolution across three scales: within individual patients, in different patients in our study, and in the global influenza population. In hemagglutinin, a small set of mutations arises independently in multiple patients. These same mutations emerge repeatedly within single patients and compete with one another, providing a vivid clinical example of clonal interference. Many of these recurrent within-host mutations also reach a high global frequency in the decade following the patient infections. Our results demonstrate surprising concordance in evolutionary dynamics across multiple spatiotemporal scales.
- Published
- 2017
- Full Text
- View/download PDF
33. Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia.
- Author
-
Boeckh M, Stevens-Ayers T, Travi G, Huang ML, Cheng GS, Xie H, Leisenring W, Erard V, Seo S, Kimball L, Corey L, Pergam SA, and Jerome KR
- Subjects
- Adult, Cohort Studies, DNA, Viral analysis, DNA, Viral genetics, Female, Humans, Male, Middle Aged, ROC Curve, Bronchoalveolar Lavage Fluid virology, Cytomegalovirus genetics, Cytomegalovirus Infections virology, Hematopoietic Stem Cell Transplantation statistics & numerical data, Pneumonia, Viral virology, Viral Load methods
- Abstract
Background: Quantitative cytomegalovirus (CMV) DNA-specific polymerase chain reaction (PCR) analysis is widely used as a surveillance method for hematopoietic stem cell transplant (HCT) recipients. However, no CMV DNA threshold exists in bronchoalveolar lavage (BAL) to differentiate pneumonia from pulmonary shedding., Methods: We tested archived BAL fluid samples from 132 HCT recipients with CMV pneumonia and 139 controls (100 patients with non-CMV pneumonia, 18 with idiopathic pneumonia syndrome [IPS], and 21 who were asymptomatic) by quantitative CMV and β-globin DNA-specific PCR., Results: Patients with CMV pneumonia had higher median viral loads (3.9 log10 IU/mL; interquartile range [IQR], 2.6-6.0 log10 IU/mL) than controls (0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with non-CMV pneumonia, 0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with IPS, and 1.63 log10 IU/mL [IQR, 0-2.5 log10 IU/mL] for patients who were asymptomatic; P < .001 for all comparisons to patients with CMV pneumonia). Receiver operating characteristic curve analyses and predictive models identified a cutoff CMV DNA level of 500 IU/mL to differentiate between CMV pneumonia and pulmonary shedding, using current CMV pneumonia prevalence figures. However, different levels may be appropriate in settings of very high or low CMV pneumonia prevalence. The presence of pulmonary copathogens, radiographic presentation, or pulmonary hemorrhage did not alter predictive values., Conclusion: CMV DNA load in BAL can be used to differentiate CMV pneumonia from pulmonary shedding., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
34. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.
- Author
-
Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Sorror ML, Sandmaier BM, Nichols G, Zerr DM, Jerome KR, Schiffer JT, and Boeckh M
- Subjects
- Adenoviridae genetics, Adenoviridae isolation & purification, Adenoviridae Infections diagnosis, Adenoviridae Infections immunology, Adenoviridae Infections virology, Adult, Area Under Curve, BK Virus genetics, BK Virus isolation & purification, Child, Cord Blood Stem Cell Transplantation mortality, Cytomegalovirus genetics, Cytomegalovirus isolation & purification, DNA, Viral genetics, Female, Graft vs Host Disease immunology, Graft vs Host Disease mortality, Graft vs Host Disease pathology, Herpesviridae Infections diagnosis, Herpesviridae Infections immunology, Herpesviridae Infections virology, Herpesvirus 4, Human genetics, Herpesvirus 4, Human isolation & purification, Herpesvirus 6, Human genetics, Herpesvirus 6, Human isolation & purification, Humans, Male, Middle Aged, Opportunistic Infections diagnosis, Opportunistic Infections immunology, Opportunistic Infections virology, Proportional Hazards Models, Real-Time Polymerase Chain Reaction, Retrospective Studies, Risk Factors, Transplantation, Homologous, Unrelated Donors, Viral Load, Adenoviridae Infections mortality, DNA, Viral isolation & purification, Hematopoietic Stem Cell Transplantation mortality, Herpesviridae Infections mortality, Opportunistic Infections mortality
- Abstract
Strategies to prevent active infection with certain double-stranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by incomplete understanding of their epidemiology and clinical impact. We retrospectively tested weekly plasma samples from allogeneic HCT recipients at our center from 2007 to 2014. We used quantitative PCR to test for cytomegalovirus, BK polyomavirus, human herpesvirus 6B, HHV-6A, adenovirus, and Epstein-Barr virus between days 0 and 100 post-HCT. We evaluated risk factors for detection of multiple viruses and association of viruses with mortality through day 365 post-HCT with Cox models. Among 404 allogeneic HCT recipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of multiple viruses was common through day 100: 90% had ≥1, 62% had ≥2, 28% had ≥3, and 5% had 4 or 5 viruses. Risk factors for detection of multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acute graft-versus-host disease ( P values < .01). Absolute lymphocyte count of <200 cells/mm
3 was associated with greater virus exposure on the basis of the maximum cumulative viral load area under the curve (AUC) ( P = .054). The maximum cumulative viral load AUC was the best predictor of early (days 0-100) and late (days 101-365) overall mortality (adjusted hazard ratio [aHR] = 1.36, 95% confidence interval [CI] [1.25, 1.49], and aHR = 1.04, 95% CI [1.0, 1.08], respectively) after accounting for immune reconstitution and graft-versus-host disease. In conclusion, detection of multiple dsDNA viruses was frequent after allogeneic HCT and had a dose-dependent association with increased mortality. These data suggest opportunities to improve outcomes with better antiviral strategies., (© 2017 by The American Society of Hematology.)- Published
- 2017
- Full Text
- View/download PDF
35. A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL.
- Author
-
Kimball LE, Stevens-Ayers T, Green ML, Xie H, Flowers ME, Jerome KR, LeBlanc R, Dahlgren C, Nichols WG, Chemaly RF, Papanicolaou G, and Boeckh M
- Abstract
Purpose: The logistics of conducting double-blinded phase III clinical trials with participants residing in remote locations are complex. Here we describe the implementation of an interventional trial for the prevention of late cytomegalovirus (CMV) disease in hematopoietic cell transplantation (HCT) subjects in a long-term follow-up environment., Methods: A total of 184 subjects at risk for late CMV disease surviving 80 days following allogeneic HCT were randomized to receive six months of valganciclovir or placebo. Subjects were followed through day 270 post-transplant at their local physician's office within the United States. Anti-viral treatment interventions were based on CMV DNAemia as measured by polymerase chain reaction (PCR) (>1000 copies/mL) and granulocyte colony stimulating factor (G-CSF) was prescribed for neutropenia (absolute neutrophil count (ANC <1.0 × 10
9 cells/L). Blood samples for viral testing and safety monitoring were shipped to a central laboratory by overnight carrier. Real-time communication was established between the coordinating center and study sites, primary care physicians, and study participants to facilitate starting, stopping and dose adjustments of antiviral drugs and G-CSF. The time required to make these interventions was analyzed., Results: Of the 4169 scheduled blood specimens, 3832 (92%) were received and analyzed; the majority (97%) arriving at the central site within 2 days. Among subjects with positive CMV DNAemia (N=46), over 50% received open label antiviral medication within one day. The median time to start G-CSF for neutropenia was <1 day after posting of laboratory results (range 0-6; N=38). Study drug dose adjustments for abnormal renal function were implemented 203 times; within one day for 48% of cases and within 2 days for 80% of cases., Conclusion: Complex randomized, double-blind, multicenter interventional trials with treatment decisions made at a central coordinating site can be conducted safely and effectively according to Good Clinical Practice (GCP) guidelines over a large geographic area., Competing Interests: Conflict of Interest Statement:- Published
- 2016
- Full Text
- View/download PDF
36. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.
- Author
-
Stachel D, Stevens-Ayers T, and Boeckh M
- Subjects
- Antiviral Agents administration & dosage, Antiviral Agents immunology, Benzimidazoles administration & dosage, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Ganciclovir immunology, Humans, Immunity, Cellular drug effects, Immunocompetence drug effects, Immunologic Tests, Ribonucleosides administration & dosage, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Cytomegalovirus drug effects, Cytomegalovirus immunology, Cytomegalovirus Infections immunology, Cytomegalovirus Infections prevention & control, Ganciclovir therapeutic use, Ribonucleosides therapeutic use
- Abstract
Background: Ganciclovir has demonstrated immunosuppressive effects in vitro which may lead to delayed cytomegalovirus (CMV)-specific immune reconstitution when the drug is given prophylactically. Maribavir is a new and more potent anti-CMV drug that is under evaluation for therapeutic use in transplant recipients., Objectives: The objective of this study was to evaluate the potential effect of maribavir on CMV-specific T cell function in comparison to ganciclovir., Study Design: In ten immunocompetent CMV seropositive donors, maribavir and ganciclovir were compared over a broad range of concentrations (0.2-500μM) regarding their effects on lymphoproliferation, CMV-specific CD4+ and CD8+ cytokine expression, T cell multifunctionality, degranulation and apoptosis., Results: Maribavir inhibited lymphocyte proliferation at concentrations of 50μM and above, however, cytokine expression, cellular degranulation and multifunctionality of CD4+ and CD8+ T cells in response to CMV lysate and pp65 peptide mix were not impaired except at the highest concentration of 500μM. Ganciclovir inhibited lymphoproliferative responses starting at 10μM. As with maribavir, other cellular responses following stimulation with CMV lysate and pp65 peptide mix were only impaired at the highest concentration of 500μM of ganciclovir. Neither maribavir nor ganciclovir showed induction of lymphocyte apoptosis., Conclusions: Maribavir exhibits a low potential to suppress CMV-specific T cell function. This finding supports the use of higher doses in the prophylactic setting than originally proposed., (Copyright © 2016. Published by Elsevier B.V.)
- Published
- 2016
- Full Text
- View/download PDF
37. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
- Author
-
Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, and Leisenring W
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents adverse effects, Cytomegalovirus genetics, Cytomegalovirus Infections immunology, DNA, Viral blood, Double-Blind Method, Female, Follow-Up Studies, Ganciclovir adverse effects, Ganciclovir therapeutic use, Humans, Immunity, Cellular, Male, Middle Aged, Neutropenia chemically induced, Polymerase Chain Reaction, Quality of Life, Treatment Outcome, Valganciclovir, Young Adult, Antiviral Agents therapeutic use, Cytomegalovirus Infections prevention & control, Ganciclovir analogs & derivatives, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Background: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined., Objective: To compare valganciclovir prophylaxis with polymerase chain reaction-guided preemptive therapy., Design: Randomized, double-blind trial. (ClinicalTrials.gov: NCT00016068)., Setting: Multicenter trial., Patients: 184 recipients of hematopoietic cell transplantation (HCT) who were at high risk for late CMV disease (95 patients received valganciclovir and 89 received placebo)., Intervention: 6 months of valganciclovir (900 mg/d) or placebo. Patients with polymerase chain reaction positivity at 1000 copies/mL or greater or a 5-fold increase over baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice daily, respectively)., Measurements: The composite primary end point was death, CMV disease, or other invasive infections by 270 days after HCT. Secondary end points were CMV disease, CMV DNAemia, death, other infections, resource utilization, ganciclovir resistance, quality of life, immune reconstitution, and safety., Results: The primary composite outcome occurred in 20% of valganciclovir recipients versus 21% of placebo-preemptive therapy recipients (treatment difference, -0.01 [95% CI, -0.13 to 0.10]; P = 0.86). There was no difference in the primary end point or its components 640 days after HCT. The incidence of a CMV DNAemia level of 1000 copies/mL or greater or a 5-fold increase over baseline was reduced in the valganciclovir group (11% vs. 36%; P < 0.001). Neutropenia was not significantly different at the absolute neutrophil count of less than 0.5 × 109 cells/L (P = 0.57); however, more patients received hematopoietic growth factors in the valganciclovir group (25.3% vs. 12.4%; P = 0.026). No significant differences were seen in other secondary outcomes., Limitation: Some high-risk patients were not included., Conclusion: Valganciclovir prophylaxis was not superior in reducing the composite end point of CMV disease, invasive bacterial or fungal disease, or death when compared with polymerase chain reaction-guided preemptive therapy. Both strategies performed similarly with regard to most clinical outcomes., Primary Funding Source: Roche Laboratories.
- Published
- 2015
- Full Text
- View/download PDF
38. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.
- Author
-
Pergam SA, Xie H, Sandhu R, Pollack M, Smith J, Stevens-Ayers T, Ilieva V, Kimball LE, Huang ML, Hayes TS, Corey L, and Boeckh MJ
- Subjects
- Adult, Antibodies, Viral blood, Cytomegalovirus Infections blood, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections immunology, Female, Humans, Incidence, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Factors, Tissue Donors, Transplantation, Homologous, United States epidemiology, Antibodies, Viral immunology, Bone Marrow Transplantation adverse effects, Cytomegalovirus immunology, Cytomegalovirus Infections transmission, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Cytomegalovirus (CMV) transmission via stem cells or marrow in CMV donor seropositive/recipient seronegative (D+/R-) hematopoietic cell transplantation (HCT) is surprisingly inefficient, and factors associated with transmission in these high-risk HCT recipients are unknown. In a retrospective cohort of D+/R- HCT recipients, cumulative incidence curve estimates were used to determine posttransplantation rates of CMV and multivariable Cox proportional models to assess risk factors associated with transmission. A total of 447 patients from 1995 to 2007 were eligible for enrollment. Overall, 85 of 447 (19.0%) acquired CMV at a median of 49 days (IQR 41-60) posttransplantation. CMV disease before day 100 occurred in 6 of 447 (1.3%) patients and in 7 of 447 (1.6%) after day 100. The donor graft, specifically the total nucleated cell count (adjusted hazard ratio [HR] 2.7; 95% confidence interval [CI], 1.4-4.7, P = .0002), was the only factor associated with CMV transmission in multivariable analyses. Notably, the source stem cells (marrow versus peripheral blood stem cell [PBSC]), screening method, and graft-versus-host disease (GVHD) were not associated with transmission. Thus, a highly cellular graft was the only identifiable risk factor associated with CMV transmission, suggesting that viral genomic content of the donor graft determines transmission efficiency in D+/R- HCT recipients., (Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
39. Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.
- Author
-
Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer B, Zaia JA, Forman S, Negrin RS, Chauncey T, Bensinger W, and Boeckh M
- Subjects
- Adolescent, Adult, Bone Marrow Transplantation methods, CD8-Positive T-Lymphocytes immunology, Child, Cytokines biosynthesis, Cytokines immunology, Cytomegalovirus Infections etiology, Cytomegalovirus Infections virology, Humans, Middle Aged, Viral Load, Young Adult, Bone Marrow Transplantation immunology, Cytomegalovirus immunology, Cytomegalovirus Infections immunology, Peripheral Blood Stem Cell Transplantation methods, T-Lymphocytes immunology
- Abstract
Peripheral blood stem cell (PBSC) products contain more T cells and monocytes when compared with bone marrow (BM), leading to fewer bacterial and fungal infections. Cytomegelovirus (CMV) viral load and disease as well as CMV-specific immune reconstitution were compared in patients enrolled in a randomized trial comparing PSBC and BM transplantation. There was a higher rate of CMV infection and disease during the first 100 days after transplantation among PBSC recipients (any antigenemia/DNAemia: PBSC, 63% vs BM, 42%, P = .04; CMV disease: PBSC, 17% vs BM, 4%, P = .03). By 2 years, CMV disease rates were similar. The early increase in CMV events correlated temporarily with lower CMV-specific CD4(+) T helper and CD8(+) cytotoxic T lymphocyte function at 30 days after transplantation in PBSC recipients. By 3 months after transplantation and thereafter, CMV-specific immune responses were similar between BM and PBSC recipients. In conclusion, higher CMV infection and disease rates occurred in PBSC transplant recipients early after transplantation. These differences may be because of a transient delay in CMV-specific immune reconstitution following PBSC transplantation., (Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
40. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.
- Author
-
Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, and Corey L
- Subjects
- Antigens, Viral blood, Antigens, Viral genetics, Antiviral Agents therapeutic use, Base Sequence, Bronchoalveolar Lavage Fluid virology, Cytomegalovirus genetics, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections etiology, DNA Primers, DNA, Viral genetics, DNA, Viral isolation & purification, Enzyme-Linked Immunosorbent Assay, Humans, Phosphoproteins blood, Phosphoproteins genetics, Predictive Value of Tests, Reproducibility of Results, Sensitivity and Specificity, Viral Load, Viral Matrix Proteins blood, Viral Matrix Proteins genetics, Cytomegalovirus isolation & purification, Cytomegalovirus Infections diagnosis, DNA, Viral blood, Polymerase Chain Reaction methods, Stem Cell Transplantation adverse effects
- Abstract
Previous studies have shown that detection of cytomegalovirus (CMV) DNA in plasma is less sensitive than the antigenemia assay for CMV surveillance in blood. In 1,983 blood samples, plasma PCR assays with three different primer sets (UL125 alone, UL126 alone, and UL55/UL123-exon 4) were compared to the pp65 antigenemia assay and blood cultures. Plasma PCR detected CMV more frequently in blood specimens than either the antigenemia assay or cultures, but of the three PCR assays, the double-primer assay (UL55/UL123-exon 4) performed best with regard to sensitivity, specificity, and predictive values compared to antigenemia: 122 of 151 antigenemia-positive samples were detected (sensitivity, 80.1%), and there were 122 samples that were PCR positive-antigenemia negative (specificity, 93%). Samples with discrepant results had a low viral load (median, 0.5 cells per slide; 1,150 copies per ml) and were often obtained from patients receiving antiviral therapy. CMV could be detected by other methods in 15 of 29 antigenemia positive-PCR negative samples compared to 121 of 122 PCR positive-antigenemia negative samples (P < 0.001). On a per-subject basis, 21 of 25 patients (antigenemia positive-PCR negative) and all 57 (PCR positive-antigenemia negative) could be confirmed at different time points during follow-up. The higher sensitivity of the double-primer assay resulted in earlier detection compared to antigenemia in a time-to-event analysis of 42 CMV-seropositive stem cell transplant recipients, and two of three patients with CMV disease who were antigenemia negative were detected by plasma PCR prior to the onset of disease. Interassay variability was low, and the dynamic range was >5 log(10). Automated DNA extraction resulted in high reproducibility, accurate CMV quantitation (R = 0.87, P < 0.001), improved sensitivity, and increased speed of sample processing. Thus, primer optimization and improved DNA extraction techniques resulted in a plasma-based PCR assay that is significantly more sensitive than pp65 antigenemia and blood cultures for detection of CMV in blood specimens.
- Published
- 2004
- Full Text
- View/download PDF
41. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
- Author
-
Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, and Boeckh M
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents therapeutic use, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes metabolism, Child, Child, Preschool, Cytomegalovirus metabolism, Dose-Response Relationship, Drug, Female, Ganciclovir therapeutic use, Humans, Infant, Lymphocytes metabolism, Male, Middle Aged, Multivariate Analysis, Time Factors, Transplantation Conditioning, Cytomegalovirus Infections prevention & control, Hematopoietic Stem Cell Transplantation methods, Transplantation, Homologous methods
- Abstract
Reconstitution of cellular immunity by 3 months after hematopoietic stem cell transplantation (HSCT) is a critical determinant of the long-term success of the transplantation. We analyzed the factors affecting recovery of cytomegalovirus (CMV)-specific CD4+ and CD8+ function at 3 months after HSCT by univariate and multivariable analyses including source of stem cells (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-versus-host disease (GVHD), steroid use, conditioning regimens, ganciclovir use, HLA matching, circulating CMV antigenemia, absolute CD4+ and CD8+ counts, and donor CMV serology. High-dose steroids and CD4+ count less than 100 x 10(9)/L were significant predictors of impaired CD4+ functional recovery in the multivariable analysis. High-dose steroids, bone marrow as a source of stem cells, and CD8+ count less than 50 x 10(9)/L were associated with impaired CD8+ function in the multivariable analysis. Steroids were found to impair both CD4+ and CD8+ function in a dose-dependent manner. In the absence of high-dose steroids, low-level subclinical CMV antigenemia was found to stimulate both CD4+ and CD8+ functional recovery in recipients of ganciclovir prophylaxis. There was no difference in immune reconstitution between those who received prophylactic ganciclovir versus antigenemia-guided pre-emptive therapy. Thus, absolute CD4+ and CD8+ counts less than 100 x 10(9)/L and 50 x 10(9)/L, respectively; bone marrow as the source of stem cells; and high-dose steroid use all predict delayed recovery of functional T-cell immunity at 3 months after transplantation. Subclinical CMV reactivation while on ganciclovir appears to be a potent stimulator of T-cell function. These findings have implications for vaccination and adoptive-immunotherapy strategies in this population.
- Published
- 2003
- Full Text
- View/download PDF
42. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.
- Author
-
Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, and Corey L
- Subjects
- Cytomegalovirus growth & development, Cytomegalovirus immunology, Cytomegalovirus Infections pathology, Humans, Immunity, Cellular, Incidence, Leukemia complications, Leukemia therapy, Longitudinal Studies, Prospective Studies, Risk Factors, Survival Analysis, T-Lymphocytes immunology, Time Factors, Transplantation, Homologous adverse effects, Viral Load, Virus Activation, Cytomegalovirus Infections etiology, Cytomegalovirus Infections mortality, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is increasingly observed. We designed a prospective cohort study to define the incidence and risk factors for late CMV infection in patients who undergo HSCT. CMV-seropositive patients were studied prospectively for CMV infection (quantitative pp65 antigenemia, quantitative CMV-DNA, blood culture), T-cell immunity (CMV-specific CD4(+) T-helper and CD8(+) cytotoxic T-lymphocyte responses, CD4 and CD8 T-cell count, absolute lymphocyte count), and other transplantation-related factors. Univariate and multivariable analyses were used to assess the risk for late CMV infection and disease and to assess overall survival. Late CMV disease developed in 26 of 146 (17.8%) patients a median of 169 days after transplantation (range, 96-784 days); the mortality rate was 46%. Thirty-eight percent of patients surviving late disease had a second episode a median of 79 days after the first episode. At 3 months after transplantation, preceding detection of CMV pp65 antigenemia, CD4 T-cell counts lower than 50 cells/mm(3), postengraftment absolute lymphopenia levels lower than 100 lymphocytes/mm(3), undetectable CMV-specific T-cell responses, and graft-versus-host disease (GVHD) were associated with late CMV disease or death. After 3 months, continued detection of pp65 antigenemia or CMV DNA in plasma or peripheral blood leukocytes and lymphopenia (fewer than 300 lymphocytes/mm(3)) were strong predictors of late CMV disease and death. In conclusion, CMV viral load, lymphopenia, and CMV-specific T-cell immunodeficiency are predictors of late CMV disease and death after allogeneic stem cell transplantation. Prevention strategies should be targeted at patients in whom CMV reactivated during the first 3 months and those with poor CMV-specific immunity or low CD4 counts.
- Published
- 2003
- Full Text
- View/download PDF
43. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
- Author
-
Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger W, Flowers ME, Martin P, Storb R, Appelbaum FR, and Boeckh M
- Subjects
- Adult, B-Lymphocytes immunology, CD4 Lymphocyte Count, Female, Filgrastim, Granulocyte Colony-Stimulating Factor pharmacology, Herpesvirus 3, Human immunology, Humans, Immunoglobulin G blood, Infections epidemiology, Infections immunology, Leukocyte Common Antigens analysis, Leukocyte Count, Lymphocyte Activation, Lymphocyte Count, Lymphocyte Subsets, Male, Middle Aged, Neutrophils, Phytohemagglutinins pharmacology, Recombinant Proteins, Simplexvirus immunology, T-Lymphocytes immunology, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Immunity
- Abstract
Allogeneic peripheral blood stem cell grafts contain about 10 times more T and B cells than marrow grafts. Because these cells may survive in transplant recipients for a long time, recipients of blood stem cells may be less immunocompromised than recipients of marrow. Immune reconstitution was studied in 115 patients randomly assigned to receive either allogeneic marrow or filgrastim-mobilized blood stem cell transplantation. Between day 30 and 365 after transplantation, counts of most lymphocyte subsets were higher in the blood stem cell recipients. The difference was most striking for CD4 T cells (about 4-fold higher counts for CD45RA(high) CD4 T cells and about 2-fold higher counts for CD45RA(low/-)CD4 T cells; P <.05). On assessment using phytohemagglutinin and herpesvirus antigen-stimulated proliferation, T cells in the 2 groups of patients appeared equally functional. Median serum IgG levels were similar in the 2 groups. The rate of definite infections after engraftment was 1.7-fold higher in marrow recipients (P =.001). The rate of severe (inpatient treatment required) definite infections after engraftment was 2.4-fold higher in marrow recipients (P =.002). The difference in the rates of definite infections was greatest for fungal infections, intermediate for bacterial infections, and lowest for viral infections. Death associated with a fungal or bacterial infection occurred between day 30 and day 365 after transplantation in 9 marrow recipients and no blood stem cell recipients (P =.008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.